Venus Concept Receives FDA 510(k) Clearance for Venus NOVA Multi-Application Aesthetic Platform
核心洞察
Venus Concept has received FDA 510(k) clearance for Venus NOVA (搜索), a next-generation multi-application platform combining electrical muscle stimulation, radiofrequency, and electromagnetic fields for non-invasive body and skin treatments.
The platform integrates FlexMAX EMS technology capable of delivering up to 100,000 muscle contractions per session across 8 muscle groups, along with proprietary (MP)² technology combining Multi-Polar RF with Pulsed Electromagnetic Fields.
Venus NOVA (搜索) is positioned to address the growing GLP-1 (搜索) medication market, with the company expecting GLP-1 usage to reach over 32 million patients globally by 2030.
Venus Concept Inc., a global leader in medical aesthetic technology, announced it has received FDA 510(k) clearance to market the Venus NOVA (搜索)™, the company's next-generation multi-application platform designed for non-invasive treatments targeting the body, face, and skin. The clearance represents the first product launch from Venus Concept's new focused R&D strategy implemented as part of its 2023 turnaround initiative.
Advanced Multi-Modal Technology Integration
Venus NOVA (搜索) integrates several proprietary technologies to deliver comprehensive aesthetic treatments. The platform combines Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² technology that merges Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology to address body contouring, muscle conditioning, skin treatments, and wrinkle and cellulite (搜索) reduction.
The system's FlexMAX EMS technology features a dual-electrode design that delivers adaptive electrical stimulation capable of safely activating up to 8 muscle groups with up to 100,000 contractions per session. The platform also incorporates 4D Body, OctiPolar™, and DiamondPolar™ applicators designed for precision, comfort, and versatility across body and facial applications.
Additional technical features include Automatic Temperature Control (ATC) for real-time monitoring and maintaining optimal treatment temperatures, and Advanced VariPulse™ technology that uses adjustable suction with positive and negative pressure to enhance RF delivery and improve circulation.
Strategic Market Positioning
"Venus NOVA (搜索) embodies the convergence of intelligent technology and proven clinical science," said Melissa Kang, Chief Product Officer for Venus Concept. The company has strategically positioned the platform to address the growing market of patients using GLP-1 (搜索) medications who experience skin laxity (搜索), facial volume loss (搜索), and body contour irregularities.
Venus Concept expects GLP-1 (搜索) usage to grow to more than 32 million patients globally by 2030, representing a significant market opportunity. "We are excited to offer our innovative, comprehensive technologies to support and address the unmet needs of our existing and future customers," Kang stated.
Connected Healthcare Technology
Venus NOVA (搜索) incorporates built-in IoT connectivity through Venus Connect™, a secure cloud-based application that provides clinics with real-time analytics, treatment insights, and automatic system optimization to enhance efficiency and profitability. This connectivity represents Venus Concept's shift toward what CEO Rajiv De Silva describes as "total practice performance" rather than just device performance.
"Our product portfolio will continue to evolve and deliver more than just leading device performance, shifting towards a focus on total practice performance; from the moment the patient enters the clinic to post-treatment management," De Silva explained.
Implementation and Market Launch
Venus NOVA (搜索) is supported by the Venus Jumpstart Program, a 30-day roadmap providing advanced clinical education, marketing enablement, and strategic implementation designed to ensure seamless integration into existing practices and accelerate business success.
The platform will be available to customers in the United States in December 2025, with global rollouts planned throughout 2026 and beyond. The company anticipates the U.S. commercial introduction of Venus NOVA (搜索) will contribute to its long-term growth profile as it penetrates what it describes as the multi-billion-dollar body and skin market.
Company Portfolio and Strategic Direction
Venus Concept maintains a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, reaching over 60 countries and 9 direct markets. The company's existing aesthetic device platforms include Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME, along with hair restoration systems including NeoGraft® and the ARTAS iX® Robotic Hair Restoration system.
The Venus NOVA (搜索) launch aligns with the company's Venus AI strategic initiative and represents a key milestone in its turnaround strategy, supported by financial backing from Madryn Asset Management (搜索), L.P., and other leading healthcare industry growth equity investors.